Gurus Find Portfolio Cures In Biotech

We introduce a new feature this week--the Gurupicks' "strong buy," based on the trading of stock pickers at Marketocracy.com. The strong buy is a single stock that the best investors are buying, but that tens of thousands of other Marketocracy investors are ignoring. In other words, these are stocks that are attracting the "smart money." With markets sliding out of fears of rate hikes and oil jitters, Marketocracy's gurus are looking a little further into the future with this buy: New Haven, Conn.-based Curagen (nasdaq: CRGN - news - people ), a biotech firm that is doing research at the molecular level in an attempt to develop drugs to treat a variety of conditions, such as cancer, obesity and diabetes. Development alliances with Abgenix (nasdaq: ABGX - news - people ) and Bayer (nyse: BAY - news - people ) help to support Curagen's operations.

Back to news